Patent classifications
A61K39/205
D-glycero-B-D-heptose 1-phosphate (HMP) conjugates and use for targeted immune modulation
Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.
Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.
Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.
Apparatus for releasably holding a socket
A socket organizer for releasably and adjustably holding socket holders is provided. The organizer has a longitudinally extending rail assembly characterized by a generally U-shaped channel. A plurality of socket holders are positioned in and slidingly engage the channel. Each socket holder has a detent assembly for releasably locking a socket. A plurality of clip members are attached to the rail assembly or to mounting posts. The clip members have socket identification indicia and are positioned over the mounting posts by way of an aperture. A positioning mechanism is provided for selectively positioning individual socket holders in the channel.
Apparatus for releasably holding a socket
A socket organizer for releasably and adjustably holding socket holders is provided. The organizer has a longitudinally extending rail assembly characterized by a generally U-shaped channel. A plurality of socket holders are positioned in and slidingly engage the channel. Each socket holder has a detent assembly for releasably locking a socket. A plurality of clip members are attached to the rail assembly or to mounting posts. The clip members have socket identification indicia and are positioned over the mounting posts by way of an aperture. A positioning mechanism is provided for selectively positioning individual socket holders in the channel.
RABIES VACCINE
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.
Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
RABIES VACCINE
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.
Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES
The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.
METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES
The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.
LYSSAVIRUS ANTIGEN CONSTRUCTS
Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.